Negative
25Serious
Neutral
Optimistic
Positive
- Total News Sources
- 2
- Left
- 1
- Center
- 0
- Right
- 0
- Unrated
- 1
- Last Updated
- 13 days ago
- Bias Distribution
- 100% Left
Biomea Fusion Shares Drop on $40M Offering
Biomea Fusion, a clinical-stage diabetes and obesity company, saw its shares fall over 25% after announcing the pricing of an underwritten public offering to raise approximately $40 million. The offering consists of about 19.5 million shares and accompanying warrants, with some investors receiving pre-funded warrants, and is priced at $2 per unit. Underwriters have a 30-day option to purchase up to an additional 3 million shares and/or warrants at a discounted price. The offering is expected to close around June 20, 2025, and is being conducted under an effective shelf registration filed with the SEC, with Jefferies as sole book-running manager. Despite a 40% stock loss over the past year, analyst sentiment remains positive, with 7 out of 9 analysts rating the stock as a 'buy' or 'strong buy' and a median price target of $17. The company maintains about 37.6 million shares outstanding and a market capitalization near $110 million.

- Total News Sources
- 2
- Left
- 1
- Center
- 0
- Right
- 0
- Unrated
- 1
- Last Updated
- 13 days ago
- Bias Distribution
- 100% Left
Negative
25Serious
Neutral
Optimistic
Positive
Related Topics
Stay in the know
Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Gift Subscriptions
The perfect gift for understanding
news from all angles.